Biogen Idec’s injectable multiple sclerosis drug, Zinbryta (daclizumab), is coming under scrutiny this week as the European Medicines Agency continues its review of the product’s safety profile following reports of serious hepatic adverse reactions including the death of a patient from fulminant liver failure.
The review is being conducted by the EMA’s Pharmacovigilance Risk Assessment Committee under an Article 20 referral initiated in summer...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?